Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30715140 | 1.00 | DHFR (0.59) | DHFRPKM | |
| Hydrochloric Acid SCHEMBL28530443 | 0.98 | DHFR (0.57) | DHFRPKM | |
| SCHEMBL28201697 | 0.88 | PKM (0.56) | DHFRPKM | |
| SCHEMBL1554275 | 0.86 | PKM (0.55) | DHFRPKM | |
| SCHEMBL29352921 | 0.86 | PKM (0.55) | DHFRPKM | |
| SCHEMBL16701417 | 0.85 | PKM (0.54) | DHFRPKM | |
| SCHEMBL9499492 | 0.85 | PKM (0.54) | DHFRPKM | |
| SCHEMBL16701413 | 0.85 | PKM (0.54) | DHFRPKM | |
| SCHEMBL30872658 | 0.85 | PKM (0.54) | DHFRPKM | |
| Benzene SCHEMBL27894272 | 0.83 | PKM (0.52) | DHFRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | claimed |
| WO-2007009681-A1 | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | claimed |
| CN-117396469-A | Inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC | 2020-12-31 | — | — | US | disclosed |
| CN-107848987-B | Process for producing nitrogen-containing heterocyclic compound and intermediate therefor | 富士胶片株式会社 | 2020-10-23 | — | — | CN | disclosed |
| US-10774073-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2020-08-27 | — | — | US | disclosed |
| EP-3665165-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | Vyera Pharmaceuticals, LLC (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2019032458-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-14 | — | — | WO | disclosed |
| EP-3411367-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | Vyera Pharmaceuticals, LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| CN-105683167-B | Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and F L T3 inhibitor | 富士胶片株式会社 | 2018-10-23 | — | — | CN | disclosed |
| WO-2017136556-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2014145625-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF ENDOCRINE CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| WO-2007009681-A1 | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | DHFR 1/4885PKM 862/4885 |
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | DHFR 6/4885PKM 1531/4885 |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | DHFR 1/4885PKM 862/4885 |
| US-11530198-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | DHFR 1/4885PKM 862/4885 |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | DHFR, DHODH, FPGS | DHFR 1/4885PKM 1424/4885 |
| US-10774073-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | DHFR 1/4885PKM 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.